On July 1, 2025, Pelthos Therapeutics Inc., formerly known as Channel Therapeutics Corporation, completed a merger with LNHC, Inc., changed its name, and executed a 1-for-10 reverse stock split, raising approximately $50.1 million from PIPE financing. After the merger, the company's common stock began trading under the ticker symbol 'PTHS' on the NYSE American.